What was the PAT in Cipla’s Q4 results?
- Answer Field
-
The PAT or Profit After tax in Cipla’s Q4 results was clocked at ₹939 Cr, an uptick of 79.1% YoY growth.
BAJAJ BROKING
Cipla Q4 FY 2023-24 results were released on 10 May 2024 with the Company generating growth in its metrics like Income rising 10% YoY, EBITDA up 13% YoY, and PAT at a record high. Trade Generics and Branded Prescription led Cipla’s winning growth trajectory.
Cipla’s Q4 results tell a growth story in the last quarter of FY24. With substantial progress across focused markets, the Company witnessed a quarter befitting of positive prospects with robust key financials. Here are 5 main financial highlights of Cipla’a Q4 results:
Explore: Cipla Share Price
As Cipla went through its last quarter of FY24, it witnessed growth across its businesses and geographies with resilience in its financial metrics and operational efficiencies. Here are some key aspects of the Company’s Q4 business achievements:
Metrics | Q4 FY24 | Q4 FY23 | YoY Growth |
Total Income from Operations | 6,163 | 5,602 | 10% |
EBITDA | 1,316 | 1,166 | 12.9% |
% of Income from Operations | 21.4% | 20.8% | 54 bps |
PAT | 939 | 524 | 79.1% |
Additional Read: Quarterly Results
Cipla’s Q4 results have laid the foundation for a great start to FY25. With the India business Chronic market share growth at more than 10% (4-year CAGR) for the Company, and other markets showing robust operations and financial strength, Cipla is about to go bigger and better in FY25. The Company is going ahead into the new financial year with a continuous growth momentum and is reserving a corpus to meet this goal. Across key therapies and segments, the Pharma major shows momentum that is structured on expansion, and this is in adherence with the Company’s plan for the next few quarters.
As a key contender in the Pharma sector, Cipla has made great breakthroughs in Q4 and FY24. The Company is making concentrated efforts to grow its main markets and open new ones. In FY24, as the Company’s Revenues crossed the threshold of ₹25,000 Cr, operating margins improved at a substantial rate and went over ₹6,000 Cr for the very first time, growing at a robust 14% on topline and 26% on profitability on a YoY basis. With prospects for increased profitability in the future months, Cipla is on track with its future aims.
Additional Read: ABB India Q4 Results
Established in 1935, Cipla is an old hand in the Pharma sector of India, making waves globally as it navigates its operations to sustain sound operations and financial goals. The aim of the Company has always been the sustenance of ‘agile growth’, especially on its home front, India. Since its inception, the Company has expanded its operations in South Africa, North America, and Emerging economies with its deepening portfolio of complex generics.
The Company’s strengths lie in the medical areas of urology, anti-retroviral, cardiology, respiratory, and CNS. Furthermore, the Company boasts a strong presence with its 47 manufacturing plants worldwide, with more than 50 dosage forms and over 1,500 products to date. Cipla has the added distinction of being ranked the 3rd largest Pharma company in India (IQVIA MAT March 2024), the largest pharmaceutical prescription market in South Africa (IQVIA March 2024), and the largest prescription drug provider in the US; Gx inhalation products (IQVIA MAT February 2024). By providing affordable healthcare for life-threatening conditions like HIV/AIDS in Africa, Cipla has made itself proud in the Pharma industry the world over.
Results for the Fourth Quarter and Full Year Ended March 31, 2024
Additional Read: venkys Q4 Results
Sources:
CIPLA Q4 Press Release on BSE
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Stock Market and Commodity Market: Meaning & Key Differences
12 Dec, 2024 | 4 Min. read
Gold Price in India | Gold Rises 1% to $2,719 Ahead of U.S. PPI Data
12 Dec, 2024 | 39 Min. read
Coca-Cola Sells 40% Stake in Bottling Arm to Jubilant Bhartia Group
12 Dec, 2024 | 2 Min. read
Indian Overseas Bank Receives ₹808.3 Crore Income Tax Refund
12 Dec, 2024 | 2 Min. read
Shakti Pumps Secures ₹754.3 Crore Solar Water Pump Order in Maharashtra
12 Dec, 2024 | 2 Min. read
Vedanta to Consider Fourth Interim Dividend on December 16
12 Dec, 2024 | 2 Min. read
Share Market Today | Flat to Positive Start Expected for Indian Markets Amid Global Cues
12 Dec, 2024 | 4 Min. read
Securities Transaction Tax: Meaning & Charges
12 Dec, 2024 | 7 Min. read
International Gemological Institute India IPO Issue Date & Pricing
12 Dec, 2024 | 4 Min. read
How to Apply for International Gemological Institute India IPO?
12 Dec, 2024 | 3 Min. read
Robo Trading: Meaning, Examples, Features & Types
12 Dec, 2024 | 6 Min. read
India’s Leading Infrastructure Stocks for 2024
12 Dec, 2024 | 6 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
The PAT or Profit After tax in Cipla’s Q4 results was clocked at ₹939 Cr, an uptick of 79.1% YoY growth.
Cipla’s India business recorded a growth in its India business segment with growth recorded at 7% YoY, mainly on the back of Branded Prescription and Trade Generics.
The Cipla Q4 results portrayed growth in key segments of Cipla’s business segments with growth on the domestic and global front. The India business saw a growth of 7% YoY, while the North America business experienced a YoY growth of 11%. The South African business was not to be left out of the growth momentum and grew 26% YoY in local currency terms.
No Result Found
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading